ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA

Rosen Law Firm is reminding investors who purchased ADMA Biologics securities between August 9, 2024 and March 25, 2026 of an August 10, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that ADMA Biologics made materially false statements and failed to disclose undisclosed related party transactions, channel stuffing practices, and inadequate internal controls.

07/13/2026, 7:21 PM • GlobeNewswire

רוזן, חברת שפתחה בהליכים ראשונה, מעודדת את המשקיעים ב-ADMA BIOLOGICS, Inc לקבל ייעוץ משפטי לפני המועד האחרון החשוב בתביעה ייצוגית בניירות ערך שהוגשה לראשונה על ידי החברה – ADMA

Rosen Law Firm reminds investors in ADMA Biologics, Inc. (NASDAQ: ADMA) of the August 10, 2026 deadline to join a securities class action lawsuit. The firm alleges that ADMA made false statements regarding undisclosed related-party transactions, channel stuffing practices, inadequate internal controls, and misleading revenue representations during the period from August 9, 2024 to March 25, 2026.

07/11/2026, 1:37 AM • GlobeNewswire

ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA

Rosen Law Firm is reminding investors who purchased ADMA Biologics securities between August 9, 2024 and March 25, 2026 of an August 10, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that ADMA Biologics made materially false statements and failed to disclose undisclosed related party transactions, channel stuffing practices, and inadequate internal controls.

07/10/2026, 2:48 PM • GlobeNewswire

Deadline Alert: ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit

A class action lawsuit has been filed against ADMA Biologics for alleged securities fraud. Culper Research published a report claiming the company engaged in channel stuffing and undisclosed related party transactions to artificially inflate revenue growth in 2025. The allegations led to a 29.1% stock price decline on March 25, 2026. Investors who purchased ADMA securities between August 9, 2024 and March 25, 2026 can file a lead plaintiff motion by August 10, 2026.

07/10/2026, 1:56 PM • GlobeNewswire

ADMA Biologics (NASDAQ:ADMA) Channel Stuffing Claims Trigger Securities Fraud Class Action – Investors Notified to Contact BFA Law about the Lawsuit

ADMA Biologics faces a securities fraud class action lawsuit after Culper Research alleged the company engaged in channel stuffing to artificially inflate 2025 revenue growth from -3% to reported +20%. The allegations triggered a 29% stock decline, with the largest single-day drop of 16.6% on March 24, 2026. Investors have until August 10, 2026, to request lead plaintiff status.

07/10/2026, 6:20 AM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against ADMA Biologics, Inc. alleging securities fraud for the period between August 9, 2024 and March 25, 2026. The complaint claims the company made false statements and failed to disclose undisclosed related party transactions, channel stuffing practices, and inadequate internal controls. Investors who suffered losses have until August 10, 2026 to request lead plaintiff status.

07/09/2026, 12:00 PM • GlobeNewswire

ADMA INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit

ADMA Biologics faces a securities class action lawsuit alleging the company made false statements regarding undisclosed related party transactions, channel stuffing schemes, and inadequate internal controls. A Culper Research report claimed ADMA's reported 20% growth was artificially inflated through extended payment terms, with actual revenue declining 3% in 2025. The stock fell over 16% following the report and an additional 13% after a Cantor Fitzgerald downgrade.

07/07/2026, 4:50 PM • GlobeNewswire

DEADLINE ALERT for BTGO, VIA, Z, ADMA: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions

Law Offices of Howard G. Smith announced securities fraud class action lawsuits against four publicly-traded companies: BitGo Holdings, Via Transportation, Zillow Group, and ADMA Biologics. The complaints allege that defendants made false or misleading statements regarding their business operations, financial performance, and prospects. Investors have until August 7-10, 2026 to file lead plaintiff motions.

07/06/2026, 1:58 PM • GlobeNewswire

Bronstein, Gewirtz & Grossman LLC Urges ADMA Biologics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

A class action lawsuit has been filed against ADMA Biologics, Inc. alleging securities fraud involving undisclosed related party transactions, channel stuffing, and inadequate internal controls during the period from August 9, 2024 to March 25, 2026. Investors who purchased ADMA securities during this period are encouraged to join the case, with a lead plaintiff deadline of August 10, 2026.

07/06/2026, 12:00 PM • GlobeNewswire

ADMA CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026

ADMA Biologics faces a federal securities class action lawsuit alleging the company made false statements about its financial performance through channel stuffing schemes and undisclosed related party transactions. An investigative report revealed ADMA artificially inflated 2025 revenue growth from -3% to +20% by inducing distributors to overstock products with rebates and extended payment terms. The stock declined 29% following the report's publication on March 24, 2026. Investors who purchased securities between August 9, 2024 and March 25, 2026 may be eligible to participate, with a deadline of August 10, 2026 to seek lead plaintiff status.

07/05/2026, 11:50 AM • GlobeNewswire

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages First Solar, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – FSLR

Rosen Law Firm has filed securities class action lawsuits against First Solar, Hub Group, and ADMA Biologics on behalf of investors. The First Solar lawsuit alleges the company made false statements regarding its capacity to manage U.S. tariff policy impacts and overstated projected performance. Investors who purchased securities during specified class periods are encouraged to join the litigation before the August 24, 2026 lead plaintiff deadline.

07/05/2026, 8:20 AM • GlobeNewswire

ROSEN, THE FIRST FILING FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA

Rosen Law Firm announces securities class action lawsuits against ADMA Biologics (NASDAQ: ADMA) and Graphic Packaging Holding Company (NYSE: GPK). ADMA investors who purchased securities between August 9, 2024 and March 25, 2026 must act by August 10, 2026 deadline. The lawsuit alleges ADMA engaged in undisclosed related party transactions, channel stuffing, and lacked adequate internal controls. GPK investors with losses exceeding $100K have a July 6, 2026 deadline.

07/05/2026, 7:43 AM • GlobeNewswire

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Nano-X Imaging Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action – NNOX

Rosen Law Firm is encouraging investors who purchased securities of Nano-X Imaging Ltd. (NNOX) between March 31, 2025 and April 17, 2026 to join a class action lawsuit. The firm alleges that Nano-X made false statements about operational efficiency and product demand, while concealing poor manufacturing alignment, increased operating expenses, and cash burn. The lead plaintiff deadline is August 11, 2026. The firm is also investigating potential securities claims for ADMA Biologics and DNOW Inc.

07/01/2026, 8:49 PM • GlobeNewswire

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages ADMA Biologics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – ADMA

Rosen Law Firm is pursuing securities class action lawsuits against ADMA Biologics, Nano-X Imaging, and DNOW Inc. on behalf of investors. The ADMA case alleges undisclosed related party transactions, channel stuffing, and inadequate internal controls during the August 2024 to March 2026 period, with an August 10, 2026 deadline for lead plaintiff claims.

07/01/2026, 8:39 PM • GlobeNewswire

Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against BitGo Holdings, Inc. (BTGO), ADMA Biologics, Inc. (ADMA), and Erasca, Inc. (ERAS) Announced by Holzer & Holzer, LLC

Holzer & Holzer, LLC announced lead plaintiff deadlines for multiple shareholder class action lawsuits against BitGo Holdings, ADMA Biologics, and Erasca, Inc. The lawsuits allege that defendants made materially false statements or failed to disclose material facts regarding business risks and practices. Investors who purchased shares during specified periods and suffered losses are encouraged to seek lead plaintiff status by the respective deadlines in August 2026.

07/01/2026, 7:00 AM • GlobeNewswire